A NEW Phase 3 trial has shown that a combination therapy of cagrilintide and semaglutide (CagriSema) can lead to substantial weight loss and improved glycaemic control in adults with Type 2 diabetes ...

The percentage of participants who achieved at least 25% weight loss was 34.7% in the CagriSema group, 14.8% in the semaglutide group and 6.5% in the cagrilintide group, while the percentage that ...

CagriSema patients lost more weight than those taking either component alone: 20.4% for the combination vs 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo.

Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. The two molecules induce weight loss by reducing hunger, ...

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss.

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled ...

CagriSema led to a 20.4% weight loss at 68 weeks vs. 3.0% with placebo in adults without diabetes. 50.7% of CagriSema users with obesity reached a BMI under 30, compared to 10.2% in the placebo ...

Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second phase III study, missing the guidance of 25%.

While CagriSema showed somewhat similar results to Lilly’s Zepbound, it is also more complicated to manufacture, which analysts mentioned could be a potential pain point going forward. In light of the ...